As of today (2023-05-27), Intercept Pharmaceuticals's weighted average cost of capital is 6.45%. Intercept Pharmaceuticals's ROIC % is -64.80% (calculated using TTM income statement data).
Intercept Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Intercept Pharmaceuticals WACC % Historical Data
The historical data trend for Intercept Pharmaceuticals's WACC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Intercept Pharmaceuticals Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
WACC %
14.60
9.91
10.22
9.83
6.87
Intercept Pharmaceuticals Quarterly Data
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
WACC %
9.16
8.81
8.32
6.87
6.77
Competitive Comparison
For the Biotechnology subindustry, Intercept Pharmaceuticals's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercept Pharmaceuticals WACC % Distribution
For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's WACC % distribution charts can be found below:
* The bar in red indicates where Intercept Pharmaceuticals's WACC % falls in comparison to its industry or sector. The grey bar indicates the WACC %'s extreme value range as defined by GuruFocus.
Intercept Pharmaceuticals WACC % Calculation
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Intercept Pharmaceuticals's market capitalization (E) is $427.709 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest two-year average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2023, Intercept Pharmaceuticals's latest two-year average Short-Term Debt & Capital Lease Obligation was $56.3055 Mil and its latest two-year average Long-Term Debt & Capital Lease Obligation was $381.443 Mil. The total Book Value of Debt (D) is $437.7485 Mil.
a) weight of equity = E / (E + D) = 427.709 / (427.709 + 437.7485) = 0.4942
b) weight of debt = D / (E + D) = 437.7485 / (427.709 + 437.7485) = 0.5058
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 3.81000000%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Intercept Pharmaceuticals's beta is 0.81.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 3.81000000% + 0.81 * 6% = 8.67%
3. Cost of Debt:
GuruFocus uses last fiscal year end Interest Expense divided by the latest two-year average debt to get the simplified cost of debt.
As of Dec. 2022, Intercept Pharmaceuticals's interest expense (positive number) was $18.779 Mil. Its total Book Value of Debt (D) is $437.7485 Mil.
Cost of Debt = 18.779 / 437.7485 = 4.2899%.
4. Multiply by one minus Average Tax Rate:
GuruFocus uses the latest two-year average tax rate to do the calculation. The calculated average tax rate is limited to between 0% and 100%. If the calculated average tax rate is higher than 100%, it is set to 100%. If the calculated average tax rate is less than 0%, it is set to 0%.
The latest Two-year Average Tax Rate is 0%.
Intercept Pharmaceuticals's Weighted Average Cost Of Capital (WACC) for Today is calculated as:
WACC
=
E / (E + D)
*
Cost of Equity
+
D / (E + D)
*
Cost of Debt
*
(1 - Tax Rate)
=
0.4942
*
8.67%
+
0.5058
*
4.2899%
*
(1 - 0%)
=
6.45%
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Intercept Pharmaceuticals's weighted average cost of capital is 6.45%. Intercept Pharmaceuticals's ROIC % is -64.80% (calculated using TTM income statement data).
Intercept Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.51(5.23%) Volume: 1,489,063 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
ICPT has been successfully added to your 
